106 related articles for article (PubMed ID: 11326704)
1. Human anti-mouse antibodies: pitfalls in tumor marker measurement and strategies for enhanced assay robustness; including results with Elecsys CEA.
Nussbaum S; Roth HJ
Anticancer Res; 2000; 20(6D):5249-52. PubMed ID: 11326704
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice.
Schwegler C; Dorn-Beineke A; Nittka S; Stocking C; Neumaier M
Cancer Res; 2005 Mar; 65(5):1925-33. PubMed ID: 15753392
[TBL] [Abstract][Full Text] [Related]
3. Solving the problem of antibody interference in commercial "sandwich"-type immunoassays of carcinoembryonic antigen.
Hansen HJ; LaFontaine G; Newman ES; Schwartz MK; Malkin A; Mojzisik K; Martin EW; Goldenberg DM
Clin Chem; 1989 Jan; 35(1):146-51. PubMed ID: 2642761
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the test methods (KRYPTOR, ES 600 and CIS-RIA) for CEA, CA 15-3 and CA 125 follow-up and ONCOCHECK-quality control.
Bauer T; Charl S; Sturm G
Anticancer Res; 2000; 20(6D):5245-7. PubMed ID: 11326703
[TBL] [Abstract][Full Text] [Related]
5. [Neoplasm markers useful for diagnosis and monitoring of colonic neoplasms].
Ławicki S; Mroczko B; Szmitkowski M
Postepy Hig Med Dosw; 2002; 56(5):617-34. PubMed ID: 12596691
[TBL] [Abstract][Full Text] [Related]
6. Measures to overcome HAMA interferences in immunoassays.
Madry N; Auerbach B; Schelp C
Anticancer Res; 1997; 17(4B):2883-6. PubMed ID: 9329554
[TBL] [Abstract][Full Text] [Related]
7. [Examination of the patient serum presenting a CEA false high value after cancer immuno-cell therapy].
Abe M; Matsuura T; Hyoki M; Abe I; Tanigawa K; Kaito K
Rinsho Byori; 2011 Aug; 59(8):763-9. PubMed ID: 21942086
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody CIBCHTB1 defining an epitope on carcinoembryonic antigen (CEA).
Meenakshi A; Kumar NS; Vijayshanker SG
Hum Antibodies; 2000; 9(4):223-9. PubMed ID: 11341176
[TBL] [Abstract][Full Text] [Related]
9. Technical performance of the Elecsys CA 72-4 test--development and field study.
Filella X; Friese S; Roth HJ; Nussbaum S; Wehnl B
Anticancer Res; 2000; 20(6D):5229-32. PubMed ID: 11326700
[TBL] [Abstract][Full Text] [Related]
10. [Radioimmunodetection of 188Re-labeled anti-carcinoembryonic antigen chimeric antibody in nude mice bearing human colon carcinoma].
Zhao ZG; Ran YL; Zheng R; Kong J; Chen SZ; Yu L; Yang ZH
Ai Zheng; 2002 May; 21(5):460-3. PubMed ID: 12452032
[TBL] [Abstract][Full Text] [Related]
11. Transient human anti-mouse antibodies (HAMA) interference in CA 125 measurements during monitoring of ovarian cancer patients treated with murine monoclonal antibody.
Oei AL; Sweep FC; Massuger LF; Olthaar AJ; Thomas CM
Gynecol Oncol; 2008 May; 109(2):199-202. PubMed ID: 18304620
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion.
Sthaneshwar P; Yap SF; Jayaram G
Malays J Pathol; 2002 Jun; 24(1):53-8. PubMed ID: 16329556
[TBL] [Abstract][Full Text] [Related]
13. cDNA cloning and sequencing of a novel monoclonal antibody to carcinoembryonic antigen and construction of a mouse/human chimeric antibody.
Shibaguchi H; Arakawa F; Imakiire T; Kuroki M; Kuroki M
Anticancer Res; 2003; 23(6a):4383-8. PubMed ID: 14666725
[TBL] [Abstract][Full Text] [Related]
14. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
15. Functional humanization of an anti-CD16 Fab fragment: obstacles of switching from murine {lambda} to human {lambda} or {kappa} light chains.
Schlapschy M; Fogarasi M; Gruber H; Gresch O; Schäfer C; Aguib Y; Skerra A
Protein Eng Des Sel; 2009 Mar; 22(3):175-88. PubMed ID: 19022801
[TBL] [Abstract][Full Text] [Related]
16. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
17. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.
Väisänen V; Peltola MT; Lilja H; Nurmi M; Pettersson K
Anal Chem; 2006 Nov; 78(22):7809-15. PubMed ID: 17105175
[TBL] [Abstract][Full Text] [Related]
18. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
19. [Basic and clinical aspects of tumor markers--with special reference to CEA].
Matsuoka Y
Rinsho Byori; 1990 Jan; 38(1):31-4. PubMed ID: 2308221
[TBL] [Abstract][Full Text] [Related]
20. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
